Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vimian Group ABVIMGF 70 EV-to-EBITDA is 14.90 as of Jul. 26, 2026, which is 42% below its 10-year median of 25.91. GuruFocus rates VIMGF with a GF Score™ of 70/100 and a GF Value™ of $2.87. The stock has 4 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Vimian Group AB ranks worse than 52.99% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vimian Group AB's enterprise value is $2,095.5 Mil.
Vimian Group AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $140.7 Mil. Therefore, Vimian Group AB's EV-to-EBITDA for today is 14.90.
The historical rank and industry rank for Vimian Group AB's EV-to-EBITDA or its related term are showing as below:
VIMGF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.42 Med: 25.91 Max: 87.54
Current: 15.51
During the past 9 years, the highest EV-to-EBITDA of Vimian Group AB was 87.54. The lowest was 13.42. And the median was 25.91.
VIMGF's EV-to-EBITDA is ranked worse than 52.99% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.4
vs VIMGF: 15.51
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Vimian Group AB (OTCPK:VIMGF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vimian Group AB's PE Ratio (TTM) for today is calculated as:
Vimian Group AB's share price for today is $2.77.
Vimian Group AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.081.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vimian Group AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Vimian Group AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vimian Group AB EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vimian Group AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vimian Group AB's EV-to-EBITDA falls into.
Vimian Group AB's current Enterprise Value is $2,095.5 Mil.
Vimian Group AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $140.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vimian Group AB (VIMGF) has a EV-to-EBITDA of 14.90 as of Jul. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vimian Group AB. This is 42% below median its historical median of 25.91. Over the past decade, Vimian Group AB's EV-to-EBITDA has ranged from 13.42 to 87.54. According to the industry distribution chart, Vimian Group AB ranks #62 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 53%.
Is Vimian Group AB's EV-to-EBITDA too high?
Vimian Group AB's current EV-to-EBITDA of 14.90 is 42% below median its 10-year median of 25.91. Over the past 10 years, this metric has ranged from a low of 13.42 to a high of 87.54. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.40. Vimian Group AB's value of 14.90 is 3.5% above this industry median. Based on the distribution chart, Vimian Group AB ranks #62 out of 117 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Vimian Group AB has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Vimian Group AB's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vimian Group AB ranks #62 out of 117 companies for EV-to-EBITDA. This places Vimian Group AB in the lower half of its industry. The industry median EV-to-EBITDA is 14.40. Vimian Group AB's value of 14.90 is 3.5% above this benchmark. Historically, Vimian Group AB's own EV-to-EBITDA has ranged from 13.42 to 87.54 over the past decade. While the company's 10-year median is 25.91 vs. the industry median of 14.40, Vimian Group AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.40, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vimian Group AB's current EV-to-EBITDA of 14.90 is 3.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vimian Group AB. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vimian Group AB's current EV-to-EBITDA is 14.90, which is 42% below median its own 10-year median of 25.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vimian Group AB stock overvalued right now?
Vimian Group AB (VIMGF) has a current EV-to-EBITDA of 14.90. The stock's GF Value™ is $2.87, compared to a current price of $2.77 — trading 3.5% below its estimated fair value. The current EV-to-EBITDA is 14.90, which is 42% below median its 10-year median of 25.91 and 3.5% above the Medical Diagnostics & Research industry median of 14.40. Vimian Group AB's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vimian Group AB (VIMGF), the current EV-to-EBITDA is 14.90 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vimian Group AB (VIMGF) Overvalued in 2026?
Based on GuruFocus' analysis, Vimian Group AB stock appears to be undervalued.
The current stock price of $2.77 is trading 3.5% below its estimated GF Value™ of $2.87.
Key valuation signals for VIMGF:
EV-to-EBITDA: 14.90 (42% below median its 10-year median of 25.91)
GF Value™: $2.87 vs. price of $2.77 (3.5% below fair value)
Industry Position: 3.5% above the Medical Diagnostics & Research median (#62 of 117)
No single metric tells the full story. See the VIMGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vimian Group AB specializes in the areas of animal health, such as specialty pharma, diagnostics, medtech, and veterinary services. It offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals, with a position within allergy, dermatology, otology, and specialized nutrition. Its geographical segments include Europe, North America, and the Rest of the world.
70GF Score
Get the complete analysis for VIMGF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIMGF has been successfully added to your 
